Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Operating Expenses (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Operating Expenses for 12 consecutive years, with $19.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses rose 46.44% year-over-year to $19.2 million, compared with a TTM value of $66.7 million through Sep 2025, up 4.72%, and an annual FY2024 reading of $69.0 million, up 135.54% over the prior year.
  • Operating Expenses was $19.2 million for Q3 2025 at Avalo Therapeutics, down from $19.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $32.8 million in Q1 2024 and bottomed at $4.0 million in Q3 2023.
  • Average Operating Expenses over 5 years is $15.5 million, with a median of $13.5 million recorded in 2024.
  • The sharpest move saw Operating Expenses tumbled 63.27% in 2023, then soared 253.59% in 2024.
  • Year by year, Operating Expenses stood at $18.2 million in 2021, then crashed by 46.37% to $9.8 million in 2022, then fell by 15.61% to $8.2 million in 2023, then soared by 64.07% to $13.5 million in 2024, then soared by 42.2% to $19.2 million in 2025.
  • Business Quant data shows Operating Expenses for AVTX at $19.2 million in Q3 2025, $19.3 million in Q2 2025, and $14.7 million in Q1 2025.